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Carcinoma of the uterine cervix is one of the most common
malignancies among women worldwide. Human papilloma-
viruses (HPV) have been identified as the major etiological
factor in cervical carcinogenesis. However, the time lag
between HPV infection and the diagnosis of cancer indicates
that multiple steps, as well as multiple factors, may be neces-
sary for the development of cervical cancer. The development
and progression of cervical carcinoma have been shown to be
dependent on various genetic and epigenetic events, especially
alterations in the cell cycle checkpoint machinery. In mam-
malian cells, control of the cell cycle is regulated by the
activity of cyclin-dependent kinases (CDKs) and their essential
activating coenzymes, the cyclins. Generally, CDKs, cyclins,
and CDK inhibitors function within several pathways, inclu-
ding the p16
INK4A-cyclin D1-CDK4/6-pRb-E2F, p21
WAF1-
p27
KIP1-cyclinE-CDK2, and p14
ARF-MDM2-p53 pathways. The
results from several studies showed aberrant regulation of
several cell cycle proteins, such as cyclin D, cyclin E, p16
INK4A, p21
WAF1, and p27
KIP1, as characteristic features of HPV-
infected and HPV E6/E7 oncogene-expressing cervical carci-
nomas and their precursors. These data suggested further that
interactions of viral proteins with host cellular proteins,
particularly cell cycle proteins, are involved in the activation
or repression of cell cycle progression in cervical carcino-
genesis.
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INTRODUCTION
Carcinoma of the uterine cervix is one of the
most common malignancies among women world-
wide. The incidence of cervical carcinoma is on
the decline, but still 370,000 new cases and 190,000
resulting deaths occur each year.
1 The develop-
ment of cervical carcinoma is a multi-step carcino-
genesis. However, the steps in the progression
from low-grade cervical intraepithelial neoplasia
to carcinoma remain unknown. Human papillo-
maviruses (HPVs) have been identified as the
major etiological factor in cervical carcinogenesis.
2
Epidemiological evidence indicates that the ma-
jority of cervical neoplasia is attributable to HPV
infection. Also, although certain HPV genes are
capable of immortalization and can cooperate in
the process of transformation, not all non-invasive
lesions progress to the full malignant phenotype.
This suggests that other cofactors are required.
Recently, it has become increasingly clear that
HPVs replicate by interfering with normal cell
cycle control mechanisms. Malignant transforma-
tion is also intimately related to these processes,
and it is likely that the oncogenic potential of
papillomaviruses lies in their ability to alter cell
cycle checkpoints, thereby leading to the accumu-
lation and transmission of genetic abnormalities.
As we know, the E6 and E7 oncoproteins of high-
risk HPVs, particularly HPV 16 and 18, bind
respectively to the p53 and Retinoblastoma (Rb)
tumor suppressor proteins, which are involved in
the regulation of growth control. Moreover, the E6
proteins of high-risk HPVs bind more effectively
to the p53 protein, leading to their degradation via
a ubiquitin-mediated pathway, than those of
lower-risk HPVs.
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The development and progression of cervical
carcinoma has been shown to be dependent on
various cellular genetic and epigenetic events,
especially alterations of the cell cycle machinery at
various checkpoints. The precise control of the cell
cycle in mammalian cells is regulated by the acti-
vity of cyclin-dependent kinases (CDK1, CDK2,
CDK4, CDK6) and their essential activating coen-
zymes, the cyclins (cyclins A, B, D, E). The kinase
activities of these CDKs are regulated by the
abundance of their partner cyclins, phosphor-
ylation by various kinases, de-phosphorylation by
cell cycle phosphatases, and interaction with
CDK-inhibitory proteins (CDKIs).
3-5
The CDK family is an important group of mole-
cules that regulate cell proliferation. In addition,
two classes of mammalian cyclin-dependent
kinase inhibitors (CDKIs) have been described: the
CIP/KIP family, comprised of p21, p27, and p57,
and the INK4 family, comprised of p15, p16, p18,
and p19.
6 The INK4 molecules specifically inhibit
cyclin D complexes by interaction with the CDK4
and CDK6 components. The KIP family is pro-
miscuous, affecting cyclin E, cyclin A/CDK2, and
cyclin B/CDK1 by binding both the cyclin and
CDK subunit.
3
In this article, we review the current knowledge
of the role of cell-cycle regulatory proteins and
their alterations in cervical cancer. CDKs, cyclins,
and CDKIs generally function within several
defined pathways, including the p16
INK4A-cyclin
D1-CDK4/6-pRb-E2F pathway, the p21
WAF1-p27
KIP1
-cyclinE-CDK2 pathway, and the p14
ARF-MDM2-
p53 pathway.
7 Each of these components plays
either a positive or a negative role in cell- cycle
control mechanisms in cervical carcinogenesis.
Alterations in CDKs, CDKIs, and cyclins can lead
to uncontrolled proliferation and might contribute
to malignant transformation of the uterine cervix.
The p16
INK4A -cyclin D1-CDK4/ 6- pRb-E2F pathway
p16
INK4A
The p16
INK4A gene maps to 9p21, contains three
exons, and encodes a nuclear phosphoprotein
with a molecular weight of 16 kDa. The p16 pro-
tein functions in the negative regulation of the cell
cycle through the inhibition of cyclin- dependent
kinases 4 and 6 and interactions with cyclin D1.
8
In the absence of p16, CDKs bind to cyclin D1,
and the Retinoblastoma protein (pRb) is phos-
phorylated. Phosphorylation of pRb leads to its
deregulation at the G1/S checkpoint, and cell
proliferation is switched on. In a variety of human
malignant tumors and cell lines, the p16
INK4A gene
is inactivated by various genetic mechanisms,
including point mutations, homozygous deletions,
and hypermethylation of CpG islands in the
p16
INK4A promoter. Kim et al. found a high per-
centage of p16 exon 2 mutations in cervical cancer
specimens.
9 Dong et al. and Nuovo et al. also
described hypermethylation of the p16 promoter,
documenting inactivation of the gene as a fre-
quent epigenetic event in cervical carcinoma.
10,11
However, mutations in p16 in these lesions have
not been confirmed.
10 In some reports, mutation
and deletion of p16 are suggested to be rare
events: no gene alterations were detected in most
studies of primary cervical carcinomas or cervical
cancer cell lines, indicating that they are not
required for the development of this tumor type.
These data are concordant with those of previous
reports.
12-14
Conflicting results about the expression of p16
protein have been obtained from studies of the
role of p16 in the pathogenesis of cervical
cancers.
9,13,15,16 Overexpression of the p16 protein
is a characteristic of displastic and neoplastic
alterations of the cervical epithelium. The portion
of p16-positive samples increases as the tumor
progresses from the CIN I to the invasive carci-
noma stage.
16 Some reports have shown that p16
expression is detectable by immunohistochemistry
in cervical neoplasia and that this expression may
be a direct result of HPV infection with resultant
inactivation of pRb, which is known to bind
p16.
15,16 Squamous cell carcinomas (SCCs), high-
grade squamous intraepithelial lesions (HSILs),
and adenocarcinomas (ACs) of the cervix have
shown increased p16 immuno-staining.
17 Klaes et
al. examined the utility of p16 immunostaining to
assess inter-observer agreement in the diagnosis
of cervical intraepithelial neoplasia (CIN). In that
study, 194 cervical cone biopsies were examined
and stained with an antibody to p16. A significant
increase in inter-observer agreement when ex-
amining p16 expression was observed. The p16
expression was restricted to cervical cancer, CINCell Cycle and Cervical Carcinoma
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2-3, and those cases of CIN 1 associated with
high-risk HPV types.
Kelley et al., however, reported that no altera-
tions in p16 expression were detected in cervical
cell lines, including 8 HPV-positive cell lines, 2
HPV-negative cell lines containing mutant Rb,
and one tumorigenic cell line derived from nor-
mal cervical cells following transfection with
HPV-16 and v-H-ras (CX16-2HR).
14 These results
confirm that mutational inactivation of p16
INK4 is
a rare event in tumor samples with compromised
Rb activity. Volgareva et al. reported that all
stages of CINs and carcinomas analyzed were
heterogeneous with respect to p16 expression.
Samples that showed expression of p16 in 25% of
cells or more were identified in a side-by-side
study with samples that stained poorly or lacked
staining. These samples are evidence that p16-
negative cervical neoplasms and carcinomas do
exist.
18
The molecular basis for overexpression of p16
in cervical squamous carcinoma remains unclear.
Some explanations include a genetic mutation or
a supragenetic event at the protein level, such as
increased half-life of the p16 protein. The interac-
tion of p16 with pRb is thought to be central to
the role of p16 in controlling cell cycle progres-
sion. It has been suggested that HPV infection
leads to HPV-E7 binding to pRb, which in turn
results in increased p16 expression. Some studies
have suggested that this process only occurs in
cases of infection by high-risk types of HPV: p16
transcription may also be directly induced by the
transcription factor E2F released from pRb after
binding of the viral oncoprotein E7.
19
p16 has been used as a biomarker for dyspla-
sia in the diagnosis of cervical squamous lesions
and has the potential to be used as an additional
screening tool.
8,20,21 The overexpression of p16 is
closely associated with high-risk HPV infection
and high-grade CIN.
22 A recent report showed
that in cervical biopsy specimens, the staining
pattern of p16 and a high percentage of p16-posi-
tive cells are closely related to infection with
high-risk HPV types 16 and 18, and with CIN 2/3.
Several studies of p16 in liquid-based cytology
specimens suggested that p16 could be used in
cervical screening as a marker for persistent
high-risk HPV infection, and HSIL could also be
useful in resolving ambiguous cases involving a
differential diagnosis of cervical neoplasia (Table
1).
23,24
Cyclin D1
The cyclin D1 (PRAD-1, CCND-1) gene maps to
11q13 and shows the characteristics of a cellular
oncogene. Expression of cyclin D1 moderately
oscillates throughout the cell-cycle, reaching peak
levels in G-phase.
7 Cyclin D1 serves as a key sen-
sor and integrator of extracellular signals in early
to mid-G1 phase, mediating its function through
binding the CDKs, histone acetylase, and histone
deacetylases to modulate local chromatin struc-
ture around the genes that are involved in regula-
tion of cell proliferation and differentiation.
25 In
addition to CDK-binding functions, a body of
evidence now indicates that D-type cyclins have
CDK-independent properties. These properties are
important for cellular growth, metabolism, and
cellular differentiation. Cyclin D1 forms physical
associations with more than 30 transcription fac-
tors and transcriptional co-regulators.
25 Several
nuclear receptors, including the androgen receptor
(AR), estrogen receptor (ER), thyroid hormone
receptor, and peroxisome proliferator-activated
receptor (PPAR), bind directly to cyclin D1 within
cultured cells.
26,27 Both basal and ligand-depen-
dent transactivation of nuclear receptors is
regulated by cyclin D1.
Genetic aberrations in the regulatory circuits
that govern transit through the G1 phase of the
cell cycle occur frequently in human cancer, and
overexpression of cyclin D1 is one of the most
commonly observed alterations.
25 One model sug-
gests that the overexpression of cyclin D1 may
serve as a driving force through its cell-cycle
regulating function. Cyclin D1 is amplified and/or
overexpressed in a substantial proportion of
different human tumors.
The role of cyclin D1 in cervical carcinogenesis
is not clearly understood, and controversial results
have been described. Cho et al. found that cyclin
D1 levels were significantly lower in HPV-positive
HSIL, invasive SCC, or adenocarcinoma compared
to HPV-negative cases and normal cervical epithe-
lium, consistent with other authors' results.
28-30
Contrary to this, the results of Nichols et al.
described elevated cyclin D1 mRNA levels inYoung Tae Kim and Min Zhao
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invasive cervical cancer that were not associated
with increased protein amounts. Additionally, un-
derexpression of cyclin D1 was shown to be
regulated at the transcriptional level in another
Table 1. Expression Status of p16 in Squamous Cervical Carcinoma
Reference No. Pathology No. of cases Expression status Technique
8. Murphy et al. cGIN 12 100% positive expression Immuno-staining
CA 11 100% positive expression
9. Kim et al. SCC 20 Mutations in exon2 PCR-SSCP
10. Dong et al. SCC 31 39% methylation MSP
CA 22 18% methylation
12. Tsuda et al. CIN 42 14.3% positive expression Immuno-staining
IC 53 43.4% positive expression
13. Hirama et al. SCC 41 No deletions or mutations Southern blot/SSCP
CC cell line 8 No deletions or mutations
15. Sano et al. SCC/CIS 34 100% strong positive Immuno-staining
GCA 16 100% positive expression
DC 15 100% positive expression
16. Klaes et al. CINI 47 100% overexpressiom Immuno-staining
7 (LR-HPV) No expression
CINII 32 100% overexpressiom
CINIII 60 100% overexpressiom
IC 60 97% overexpressiom
18. Volgareva et al. CINI 51 37.3% positive expression Immuno-staining
CINII 38 31.6% positive expression
CINIII 24 66.7% positive expression
IC 21 95.2% positive expression
AC 5 100% positive expression
21. Murphy et al. cGIN 5 100% positive expression Immuno-staining
CINI 33 100% positive expression
CINII 38 100% positive expression
CINIII 46 98% positive expression
IC 10 100% positive expression
22. Guo et al. LSIL 107 57.9% positive expression Immuno-staining
HSIL CIN2/3 103 97.1% positive expression
23. Saqi et al. LSIL 27 74% positive expression Immuno-staining
HSIL 10 90% positive expression
SCC 1 100% positive expression
24. Hu et al. CINI 45 44% positive expression Immuno-staining
CINII 46 93% positive expression
CINIII 51 100% positive expression
cGIN, cervical glandular intraepithelial neoplasia; CA, Cervical adenocarcinoma; SCC, squamous cell carcinoma; CIN, cervical intrae-
pithelial neoplasia; LSIL, low-grade squamous intraepithelial; HSIL, high-grade squamous intraepithelial; IC, invasive carcinoma; CIS,
carcinomas or carcinoma in situ; GCA, genital condyloma acuminate; DC, dysplasia of the cervix; LR-HPV, low-risk HPV; MSP,
methylation-specific PCR; PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism.Cell Cycle and Cervical Carcinoma
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study.
29-32 Almost all research data suggests that
cyclin D1 expression is not found to correlate sig-
nificantly with clinicopathological factors (histolo-
gical type, tumor grade and stage, patient's
age).
33,34 Conversely, despite an underexpression
of cyclin D1 in cervical carcinomas compared to
normal cervical epithelium, positive immuno-
staining, which was found in 28-32% of invasive
carcinoma samples, was significantly associated
with poor disease-free and overall survival.
29,34
The latter report is the only one showing cyclin
D1 gene amplification in cervical carcinomas
(24%), but this was not correlated with overex-
pression.
Contradicting results have been reported about
overexpression of cyclin D1 in immunostaining
studies of cervical carcinoma. One study showed
overexpression of cyclin D1 in 3% of patients,
while underexpression was reported in another
study.
31,33 No significant increase in cyclin D1
protein levels, despite overexpression of cyclin D1
mRNA demonstrated by in situ hybridization, was
reported in cervical carcinoma.
28,29 These dis-
crepancy might be attributed to the use of differ-
ent antibodies, different scoring criteria for the
detection assay, and the varying tumor tissue
characteristics in different studies. In addition,
some studies showed that the level of cyclin D1
was significantly lower in CIN and SCC compared
with normal epithelium and that these levels
correlated significantly with HPV positivity.
28,33
Also, there is a low prevalence of G1 cyclins in
cell lines with a mutated Rb gene, and DNA
tumor virus infection can supplant tumor cell re-
quirements for cyclin D1 protein.
Cyclin D1 levels are reported as significantly
lower in HPV-positive LSIL, HSIL, invasive SCC,
or AC compared to HPV-negative cases and nor-
mal cervical epithelium.
28,30,35 Cyclin D1 and HPV
E7 possess similar binding regions for pRb and
pRb-related pocket proteins, and inactivation of
pRb either by the cyclin/CDK complexes in G1 or
by interaction with the high-risk HPV oncoprotein
E7 may result in a decreased expression of cyclin
D1 (Table 2).
CDK4
The D-type cyclins (D1, D2, and D3) and their
catalytic partners CDK4 and CDK6 act early in the
G1 phase of the cell cycle.
3 Mitogen-induced sig-
nal transduction pathways promote the activation
of cyclin D/CDK complexes at many levels, in-
cluding gene transcription, cyclin D translation
and stability, assembly of D cyclins with their
CDK partners, and import of the holoenzymes
into the nucleus, where they ultimately phos-
Table 2. Expression Status of Cyclin D1 in Squamous Cervical Carcinoma
Reference No. Pathology No. of cases Expression status Technique
28. Cho et al. CIN 22 CI 0.87% underexpression Immuno-staining
SCC 39 CI 5.88% underexpression
29. Bae et al. CINIII 31 3% underexpression Immuno-staining
SCC 32 28% underexpression
30. Southern et al. LSIL 26 (LR HPV) 92% overexpression Immuno-staining
29 (HR HPV) 87% overexpression
31. Nichols et al. LSIL 5 60% overexpression Southern blot/SSCP
HSIL 8 12.5% underexpression
SCC 18 77.8% overexpression Immuno-staining
32. Kurzrock et al. SCC cell line 10 No expression Northern blot
33. Skomedal et al. SCC 74 3% underexpression Immuno-staining
34. Cheung et al. SCC 60 32% overexpressiom Immuno-staining
*Kim et al. SCC 41 Not different RT-PCR/ Western blot
CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; LSIL, low-grade squamous intraepithelial; HSIL, high- grade
squamous intraepithelial; LR HPV, low risk HPV; HR HPV, high risk HPV; CI, cyclin index; RT-PCR, real-time polymerase chain reaction.
a not published. *Authors of this review.Young Tae Kim and Min Zhao
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phorylate their substrates. The cyclin D-dependent
kinases (CDK4 and CDK6) can phosphorylate Rb
family members (Rb, p107, and p130), thus helping
to inactivate their transcriptional corepressor
activities.
Aberrantly expressed CDK4 could play an im-
portant role in cervical tumorigenesis. It is pos-
tulated that CDK4 oscillates between the INK4
and KIP inhibitors, blocking their suppressor acti-
vity. In cervical cancer, the demonstrated lower
levels of INK4 molecules and the high levels of
CDK4 would favor binding of the more abundant
KIP inhibitors to these kinases, undermining their
inhibition of cyclin E. Thus, in this situation
Cyclin D is expendable. The E7 would deregulate
pRb initially, unleashing E2F-induced cyclin E
expression; the overexpressed CDK4 would tether
the KIP molecules, allowing cyclin E to become
sufficiently active to phosphorylate and inactivate
pRb and p27, perpetuating its own activity and
that of E7.
4,36,37
Yoshinouchi et al. found overexpression of
CDK4 in 72.6% of cervical cancer specimens;
38 this
value was consistent with previous studies of
cervical carcinoma.
33,34 In another study, CDK4
gene amplification was described in 25% of cer-
vical cancers, whereas no mutations in exon 2 of
the CDK4 gene were found.
34 To determine
whether alterations of p16 might be involved in
HPV-positive cervical cancers, Yoshinouchi
looked for gene alterations and changes in the
ability of the p16 protein to interact with CDK4
in 5 cervical cancer cell lines. No alteration of this
gene was detected, and the p16 and CDK4 pro-
teins were normally expressed. Additionally, the
ability of p16 to interact with CDK4 was not
abrogated in these cell lines. These cell lines were
HPV-positive and carried wild-type p53 genes.
These findings suggest that phosphorylation of
pRb by CDK4 is not critical in the carcinogenesis
or in the establishment of HPV-positive cervical
cancer cell lines, since the HPV viral-transforming
proteins E6 or E7 inactivate p53 and pRb tumor
suppressor protein function, resulting in deregu-
lated progression of the cell cycle.
38 So far, re-
search studies have not found a correlation
between amplification and overexpression of
CDK4 and patient age, histological tumor type, or
tumor grade or stage.
33,34
To release cells from G1 arrest and to promote
entry into S-phase, pRb is phosphorylated, and
thereby inactivated, by the cyclin D1/CDK4 com-
plex. This inactivation may also be achieved by
the interaction of pRb with the viral oncoprotein
E7, leading to the hypothesis that up-regulation of
positive regulators upstream of pRb might be
dispensable in high-risk HPV-infected cervical
carcinomas. Interestingly, very recent work has
indicated that cyclin D/CDK4 complexes also
phosphorylate Smad3, negatively regulating the
functions of transcriptional complexes that medi-
ate cell growth inhibition by proteins of the TGF
family.
39 Importantly, several lines of evidence
indicate that cyclin D/CDK complexes play a
second noncatalytic role in G1 progression by
sequestering proteins of the Cip/Kip family, in-
cluding p27
KIP1 and p21
CIP1, two potent inhibitors
of CDK2.
40,41
pRb/E2F
The retinoblastoma tumor suppressor gene (Rb)
encodes the nuclear phosphoprotein pRb (p105),
which has been found mutated or deleted in
several types of human cancer. p105Rb and other
Rb family members p107 and p130 regulate the
activity of E2F transcription factors.
42 Complexes
consisting of E2F and hypophosphorylated p105Rb
repress the transcription of genes that are required
for cell cycle progression, and repression is re-
lieved by CDK-mediated phosphorylation of
p105Rb.
43 pRb is subject to regulation by many
factors, including E2F and cyclin D1. The hypo-
phosphorylated pRb, complexed with a transcrip-
tion factor, serves as a transcriptional activator of
cyclin D1 by binding to its promoter. On the other
hand, inactivation of pRb by phosphorylation via
the cyclin D/CDK complex in late G1 would not
only unleash E2F transcription factors, but would
also decrease cyclin D1 expression.
3,44 D-Type
cyclins interact with pRb pockets through their
NH2-terminal L-X-C-X-E motifs. These are similar
to DNA virus oncoprotein region 2, such as region
2 from HPV E7.
45 Thus, the oncoprotein may
occupy the pRb pocket and displace E2F factors,
preventing pRb/E2F from inducing cyclin D1
transcription and undermining its normal growth-
suppressive function.
Some immunohistochemical studies of pRb inCell Cycle and Cervical Carcinoma
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human cancer and in normal tissues, including the
uterine cervix, have shown that pRb is expressed
in mature and differentiated cells. Both binding
and degradation of the Rb proteins by the HPV
E7 protein are essential for sustained proliferation
of HeLa cervical carcinoma cells, and E7 repres-
sion triggers senescence at least in part by acti-
vating the Rb pathway in both HeLa and HT-3
cells.
42 Salcedo et al. observed that the majority of
cells in the proliferating basal layer of the normal
epithelium displayed low levels of pRb. pRb
immunostaining in invasive cervical lesions is
frequently lower than in SIL.
43 This low expres-
sion of Rb may result from Rb gene mutations or
downregulation mechanisms, but may also be
related to pRb inactivation resulting from complex
formation with high-risk HPV E7 oncoproteins.
Rb immunoreactivity was not affected by high-
risk HPV infection in most studies of cervical
squamous cell carcinoma.
46 In contrast, Rb staining
was even more frequently found in SIL and in-
vasive cancer (93%) compared to normal epithe-
lium or reactive atypia (78%).
47 Mutations in the
Rb gene seem to be rare events in cervical can-
cer.
46,48 In most studies, Rb gene expression did
not strictly correlate with the HPV status,
49 al-
though Scheffner et al. reported a higher Rb
mutation rate in HPV-negative than in HPV-posi-
tive cervical cancer cell lines. These mutations re-
sulted in aberrant proteins that were not phos-
phorylated and unable to complex with the ade-
novirus E1A oncoprotein.
50 Cyclin D1 is the regu-
latory subunit of the holoenzymes that phos-
phorylate and, together with sequential phos-
phorylation by cyclin E/CDK2, inactivate the cell-
cycle inhibiting function of the pRb protein. The
hypophosphorylated form of pRb, complexed
with E2F, serves as an activator of cyclin D1 tran-
scription by binding to its promoter, thus driving
cyclin D1 in early and mid G1-phase of the cell
cycle. As D-type cyclins and HPV E7 possess
similar binding regions for pRb and pRb-related
pocket proteins, inactivation of pRb either by the
cyclin/ CDK complexes in G1 or by interaction
with the high-risk HPV oncoprotein E7 may result
in a decreased expression of cyclin D1 (Fig. 1).
43,51
The p21
WAF1/ CIP1-p27
KIP1-cyclin E-CDK2 pathway
p21
WAF1/CIP1
p21
WAF1/CIP1 is a cyclin-dependent kinase inhibi-
tor that associates with a class of CDKs and
inhibits their kinase activities, leading to cell cycle
arrest and the dephosphorylation of pRb. A large
body of evidence suggests that p21
WAF1/CIP1 plays
an important role in cell fate decisions during
growth and differentiation. The p21
WAF1/CIP1 pro-
tein is a p53-inducible protein that inactivates the
cyclin/CDK complexes, blocking the cell cycle
progression in the G1-S transition. p21
WAF1/CIP1 is
expressed in cells undergoing either G1 arrest or
apoptosis by p53-dependent or -independent
mechanisms.
52,53 Mutations in the p21
WAF1/CIP1
gene were very rarely detected in cervical carci-
Fig. 1. Schematic presentation of the
HPV viral oncoproteins E6/E7 and
cell-cycle regulatory proteins in cer-
vical carcinogenesis.Young Tae Kim and Min Zhao
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noma.
p21
WAF1/CIP1 expression usually correlates with
favorable prognoses in ovarian, gastric, colorectal,
and superficial bladder cancers and in esophageal
squamous cell carcinoma. However, in cervical
cancer, the conclusions about p21 expression and
its prognostic importance vary considerably.
Many authors found increased p21 expression in
invasive carcinomas
33 and an increase in the num-
ber of p21-expressing cases during the progres-
sion from normal epithelia through precancerous
lesions to invasive cervical cancer.
29,54 However,
others detected an underexpression of p21 in
micro-invasive and invasive cervical cancer
compared to normal cervical epithelium.
55,56 Van
de Putte et al.
57 did not find any expression of p21
in normal squamous cervical epithelium, in agree-
ment with Giannoudis and Herrington
58 and
Skomedal et al.,
33 but in contrast with other
reports.
29,55 Longer antibody incubation and the
use of chronic cervicitis as normal controls may
partially account for the differences. However, in-
creased expression of p21 in SCC compared to
normal epithelium was found in all cases in the
abovementioned studies.
29,33,55,59 An increase in
p21 levels in invasive cancer seems at odds with
its function of cell cycle control. However, the p21
level is probably increased in a futile attempt to
overcome its impaired or bypassed function. In
squamous cell carcinoma, its function could be
impaired through the inactivation of p21 by the
HPV-16 E7 oncoprotein. Other possibilities in-
clude inactivating mutations, mutation of its tar-
gets, overexpression of its targets sufficient to
titrate p21, or overexpression of proteins in more
downstream pathways in cell cycle control.
29
On the other hand, Lu et al. reported that ex-
pression of p21
WAF1/CIP1 was correlated with a
favorable prognosis in adenocarcinoma of the uter-
ine cervix.
60 In most studies, however, there was
no significant association of p21 expression and
clinicopathological factors or prognosis.
29,55,61,62 Al-
though the literature on the prognostic signifi-
cance of p21 expression in other human cancer
types is extensive, no clear picture can be drawn.
p27
Kip1
p27
Kip1 is a negative regulator of the G1 phase
of the cell cycle. The p27
Kip1 gene is a tumor sup-
pressor gene and is frequently lost in tumor cells.
It has been implicated in the negative regulation
of cell proliferation in response to extracellular
signals and is induced upon serum deprivation. In
normal epithelial cells, increased expression of
p27
Kip1 mediates the arrest of cells in the G1 phase
of the cell cycle when induced by TGF-β, contact
inhibition, or growth in suspension.
63 p27 asso-
ciates mainly with the cyclin E/CDK2 complex
and, through this complex, inhibits pRb phos-
phorylation. Overexpression of p27 blocks the cell
from entering S-phase.
64 Although p27
Kip1 is a
putative tumor-suppressor gene, mutation or
homozygous deletion of this gene is rarely found
in human cancer.
65 Evidence that p27 may be in-
volved in human tumor progression comes largely
from studies that have directly measured the
expression of p27 protein in clinical tumor
samples using immunohistochemical assays. A
decrease or absence of p27 protein expression has
been shown to be associated with more aggressive
clinical behavior in a variety of human tumors,
including breast, lung, colon, gastric, and ovarian
carcinoma.
65
Goff et al. found that p27 was strongly ex-
pressed in the normal cervix, in both the epithe-
lium and the stroma.
66 Other investigators have
also found high levels of p27 expression in normal
cervix.
33,67 Shiozawa et al. revealed that the ex-
pression of p27 in the normal squamous epithe-
lium of the uterine cervix was observed mainly in
the cells of the intermediate and superficial layers,
but the expression of p27 was weak in the para-
basal cells, which replicate most actively.
64 This is
consistent with a previous study by Troncone et
al.
68 In contrary, some studies have indicated that
p27 expression is significantly lower in patients
with cervical carcinoma compared with normal
epithelium and dysplasia.
67,68 Huang et al. showed
that expression of this protein was absent in 55.3%
of the invasive carcinoma tumors.
65 The trend of
reduced p27 expression in microinvasive and
invasive carcinomas further supports the notion
that p27 plays a tumor suppressor function during
neoplastic transformation in cervical epithelium.
Sgambato demonstrated that a decrease in p27
expression is associated with the development of
cervical cancer and may play an important role in
the early stage of cervical tumorigenesis.
69 In fact,Cell Cycle and Cervical Carcinoma
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in that study, p27 expression was already reduced
in preinvasive lesions of the cervix and became
progressively more evident during the progres-
sion from low- to high-grade SIL and from SIL to
carcinoma. This result of p27 expression in cer-
vical carcinomas is in agreement with similar
findings in several other types of human malig-
nancies
63 and with previous reports of cervical
cancers.
64,65,68
The lower levels of p27 in invasive cervical
carcinomas compared with normal epithelium
might be explained simply as a direct conse-
quence of the increased cell proliferation, re-
flecting the fact that the time spent by the neo-
plastic population in the early part of the cell
cycle is reduced.
68 Shiozawa et al. demonstrated
that p27 seemed to be involved in the regulation
of growth and differentiation in the normal squa-
mous epithelia of the uterine cervix.
64 Thus, the
apparently normal function of p27 may be pre-
served in preinvasive CIN lesions. However,
invasive SCC samples showed a paradoxic over-
expression of p27, which may represent aberrant
regulation and/or function of the p27 protein.
Most studies indicate that low levels of p27 are
not found to be predictive for reduced survival
and do not correlate with age, menopausal status,
tumor stage, grade of differentiation, histological
type, or HPV infection.
33,62,65,67 However, Huang et
al. demonstrated that loss of p27 expression was
significantly associated with lymph node metas-
tasis.
65 Contrary to that, in a study by Dellas et al.,
high levels of p27 were associated with poor
survival in invasive cervical carcinomas of clinical
stage IB.
70
In summary, p27
Kip1 expression is often shown
to be detectable only in a small percentage of
cervical cancers
33,67 and to be lower in cervical
carcinoma compared with normal epithelium and
precancerous lesions.
62,64,65,68 No relationship was
observed between expression of p27
Kip1 and
proliferative activity in cervical cancer as well as
in other cancers, suggesting that deregulated ex-
pression of p27
Kip1 might contribute to tumor
formation through mechanisms other than in-
creased cell proliferation.
64,68
Cyclin E
Cyclin E exists in two isoforms with high
homology, designated cyclin E1 and E2. No major
differences in expression or function between cy-
clin E1 and E2 have been found, and their ex-
pression has been assumed to be governed by the
same molecular circuitry.
71,72 Cyclin E, whose
catalytic partner is CDK2, is another rate-limiting
regulator of the G1 phase of the cell cycle,
73 and
increased expression of cyclin E has been found
in several types of tumors. Appropriate regulation
of this cyclin is essential for S-phase transition and
numerous processes that determine the accuracy
of chromosome replication. It can play a role simi-
lar to that of cyclin D1, driving the cell cycle by
phosphorylation of Rb, p107, and p130 and the
subsequent release of E2F and transcription of key
proteins. Cyclin E appears in late G1 after passage
through the restriction point. The level of cyclin
E peaks in late G1 and disappears again in early
S phase.
Even though gene amplification and post-tran-
scriptional modification are the common causes of
aberrant cyclin E expression in different malig-
nancies, high-risk-HPV oncoprotein-associated
mechanisms might contribute to the aberrant
cyclin E expression in cervical lesions. Untethering
of E2F factors by the action of the HPV E7 protein
could result in the overexpression of cyclin E. This
connection, however, is not enough to explain the
highly expressed cyclin E in cervical epithelium.
The HPV oncoprotein E7 was demonstrated in
complexes with cyclin E and cyclin A, thus elimi-
nating phase-dependent variation in activity.
Also, the HPV E7 was found to interact with p21
and thereby block p21-mediated inhibition of
cyclin E-associated kinase activity.
5,75
In normal cervical squamous epithelium, cyclin
E expression was not immunohistochemically de-
tectable or was very weak.
28,64,67,74,76 However,
cyclin E expression was increased in both low-
and high-risk HPV-infected squamous and glan-
dular lesions.
28,70 Cyclin E expression correlated
strongly with morphologic features of the HPV-in-
fected lesions, and has been observed in inter-
mediate, and partly in superficial, cells from LSIL
and HSIL, implying sequential dysregulation.
77 A
positive correlation between cyclin E expression
and cell proliferation rate in precancerous lesions
was demonstrated by some studies.
70,78 In con-
trast, Kanai et al. showed lower proliferation ratesYoung Tae Kim and Min Zhao
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in cyclin E-positive than in cyclin E-negative squa-
mous cervical carcinomas, and Quade et al. found
cyclin E staining more frequently in more differ-
entiated areas of invasive cancer.
74,79 HPV-infected
cancer was found to express cyclin E significantly
more frequently than HPV-negative cases, but this
expression was not related to prognostically im-
portant factors including age, tumor size, and
tumor type.
67 This is in accordance with the only
other study on the prognostic significance of cy-
clin E in squamous carcinoma.
Cyclin E overexpression or over-activity may be
the direct result of the presence of the HPV E6
and E7 proteins in invasive disease. The presence
of HPV E7 leads to inactivation of pRb and in-
creased transcription of cyclin E. The HPV E7
oncoprotein inactivates p27, leading to decreased
inhibition of cyclin E.
75 Southern et al. reported an
up-regulation of cyclin E and cyclin A expression
in cases of both low-risk and high-risk HPV infec-
tion.
76
CDK2
CDK2 probably functions as an effector through
phosphorylation of key substrates such as the
transcription factor p53, the cell cycle regulating
phosphatases cdc25A/cdc25C, MDM2, BRCA1,
and the transcription factor E2F1.
80 CDK2 can
have an apoptosis-sensitizing effect and can arrest
the cell cycle at different stages.
E-type cyclins (E1 and E2) govern the activity
of the single catalytic subunit of CDK2. Unlike
various combinations of D-type cyclins that are
expressed in different cell types, cyclin E-CDK2
complexes are periodic and maximal at the G1- to
S-phase transition.
81 Cyclin E-CDK2 also prefer-
entially phosphorylates pRb at different sites from
the cyclin D-dependent kinases, and these modi-
fications may differentially impact on the interac-
tions of pRb with E2Fs, histone deacetylases, and
other chromatin-remodeling proteins.
82 One of the
most significant consequences of pRb inactivation
is activation of cyclin E/CDK2 subunits, often as
a result of increased cyclin E expression. Cyclin
E/CDK2 complexes can themselves participate in
maintained inactivation of pRb in tumor cells.
The HPV oncoprotein E7 may abrogate p21-
mediated sequestration of cyclin E and render its
catalytic partner CDK2 resistant to p27.
83 Expres-
sion of CDK2 was observed in parabasal cells of
normal squamous epithelium, which was in-
versely correlated to p27 expression. Shiozawa et
al. revealed that no p27 expression was observed
in atypical epithelial cells of SIL with elevated
expression of Ki-67, cyclin E, and CDK2.
64 The
expression of cyclin-dependent kinases (CDK2
and cdc2) was also increased in a considerable
number of invasive cervical carcinomas.
64,79 In
those cases, p27 expression was also high and
retained the ability to bind to CDK2, but the p27/
cyclin E/CDK2 complex still possessed phos-
phorylating activity.
64 CDK2 also regulates the cell
cycle through its interactions with cyclin A2; thus
its functions extend beyond G1 regulation to
govern events in S and G2/M as well. Whereas
maximal periodic cyclin E-CDK2 activity is
detected at G1/S, low levels of cyclin A-CDK2
activity are first detected in late G1 phase.
Consistent with crucial roles for cyclin E/CDK2
downstream of pRb, many tumor cells are ex-
tremely sensitive to inactivation of cyclin E/CDK2
whether or not they express pRb. This conclusion
has been drawn from a multitude of studies de-
monstrating antiproliferative effects of overex-
pression of p27
Kip1, a protein inhibitor of CDK2, or
of dominant-negative CDK2 subunits. Further,
injection of antibodies against the CDK2 activators
cyclin E and cyclin A blocks proliferation, as does
treatment of many different cells with CDK2
inhibitors.
84,85
The p14
ARF-MDM2-p53 pathway
p14
ARF
The CDK
N2A gene on human chromosome 9p21
encodes two distinct proteins, p14
ARF and p16
INK4A,
which arise from the same gene by alternative
mRNA splicing.
86 p14
ARF has a mass of 15 kDa and
is translated from mRNAs bearing a unique first
exon, called 1-beta, located 15 kb upstream of the
exon 1-alpha of p16
INK4A. Both transcripts share
common exons 2 and 3. p14
ARF functions as a cell
cycle regulator, stopping cell growth at the G1-S
border and also at G2-M.
87 p14
ARF interaction in-
hibits the MDM2 oncoprotein, thereby blocking
formation of the MDM2-p53 complex and pre-
venting MDM2-induced p53 degradation.
88
Kanao et al. reported that the overexpression ofCell Cycle and Cervical Carcinoma
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p14
ARF and p16
INK4A is strongly associated with
HPV-positive cervical cancers and that reduced
expression of p14
ARF and p16
INK4A is correlated
with HPV-negative cervical cancers.
86 These find-
ings may indicate that impaired p14
ARF and
p16
INK4A mRNA expression contribute to tumor
development in HPV-negative cervical cancers by
failure to support p53 and Rb instead of their
inactivation by HPV E6 and E7.
In human fibroblasts, it has been shown that
p14ARF-induced cell cycle arrest is p53- depen-
dent and is abrogated by the co-expression of the
HPV E6 protein.
89,90 Therefore, upregulation of
p14ARF is a consequence of inactivation of p53
rather than a sign of cell cycle inhibition. Brooks
et al. demonstrated that the expression levels of
p14ARF were clearly elevated in 84% of cervical
cancers and 79% of CIN III relative to matched
normal tissue by RT-PCR.
91 Interestingly, immu-
nocytochemical analysis revealed that p14
ARF was
abundantly expressed in almost all cases of both
cervical SCC and CIN III and was overexpressed
with p73 in a great majority of cases. The frequent
simultaneous overexpression of p14
ARF with p73 is
consistent with E2F1-driven expression of both
genes. p73 has structural and functional homo-
logies to p53, including sequence-specific DNA
binding and transactivation.
92
MDM-2
The cellular protein MDM-2 is encoded by the
mdm-2 oncogene and has been shown to bind to
the p53 protein, inactivating its ability to function
as a transcription factor.
93 MDM-2 is a zinc finger
protein composed of 491 amino acids. The MDM-2
protein interaction with p53 to form the p53/
MDM-2 complex covers the p53 N-terminal acidic
or activation domain required for activation of
transcription.
94 This is the same region of the p53
DNA binding domain bound by the HPV E6
protein, thus blocking transcriptional activation.
Whether MDM2 acts solely through the inhibition
of p53 or has additional activities remains to be
determined.
The mdm-2 gene can be de-regulated in soft-
tissue sarcomas, bladder carcinomas, renal-cell
carcinomas, and breast carcinomas.
95-97 Dellas et al.
analyzed the altered patterns of MDM-2 and p53
expression in cervical neoplasms and detected
MDM-2 as well as p53 in all histological grades
of cervical neoplasia.
95 The fraction of positive
cells for MDM-2 ranged from 0 to 31% in CIN
cases and from 0 to 81% in invasive carcinomas.
The percentage of p53-stained neoplastic cells
ranged from 0 to 40% in CIN cases and from 0
to 69% in invasive carcinomas. Dellas et al. de-
monstrated that aberrant MDM-2 and p53 expres-
sion is frequently found in cervical neoplasia.
Skomedal et al. found that MDM2 may protect
against HPV-induced p53 protein degradation.
95
In contrast to the above-mentioned results, Lie
et al. reported that there is no correlation between
HPV status and expression of the cell cycle regu-
lators p53, MDM-2, and p21.54 Inactivation of p21
and p53 protein may be important, and MDM-2
abnormalities seem to play a minor role in the
development of high-grade CIN. Ikenberg et al.
found that p53 mutation and amplification of the
mdm-2 oncogene are rare, even in HPV-negative
primary cervical carcinomas.
98 In contrary, Tsuda
et al. found strong expression of MDM-2 was
higher in invasive cancers (32.1%) than in CINs
(7.1%).
12 Troncone et al. reported that immunosta-
ining for MDM-2 and p21
WAF1 was not abrogated
in invasive cervical cancer by high-risk HPV
genomic sequences, and there were no significant
differences in the expression of p53, MDM-2, and
p21
WAF1 between the HPV DNA-positive and
-negative groups, as similar levels of expression
were observed.
99
p53
The TP53 gene, present on chromosome 17p,
acts as a tumor suppressor gene, controlling entry
into the S-phase of the cell cycle, and p53 plays
many important roles in cell proliferation. Muta-
tion of this gene inactivates its suppressor activity
and is related to tumor progression.
100 The p53
tumor suppressor gene encodes a transcriptional
factor central in the regulation of cell growth,
DNA repair, and apoptosis induction. Its activity
requires the induction of several target genes,
including MDM-2 and p21
WAF1.
99
The TP53 gene is lost or mutated in over 50%
of human cancers. However, in contrast to many
other human tumor forms, TP53 mutations are
only rarely detected in cervical cancer.
101,102 A
great amount of research data suggests that theYoung Tae Kim and Min Zhao
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inactivation of p53 is believed to play a major role
in the carcinogenesis of the uterine cervix. Two
different mechanisms may explain the loss of p53
function in cervical cancer-a somatic gene muta-
tion which leads to an inactive form and/or the
enhanced protein degradation promoted by the E6
oncoprotein of HPV type 16 and type 18. Horner
et al. found that sustained inactivation of the p53
pathway by the E6 protein is required for mainte-
nance of the proliferative phenotype of HeLa
cervical carcinoma cells.
103 Troncone's results are
consistent with several other reports, indicating
that p53 immunostaining occurs in the vast ma-
jority of cervical cancers. This report also confirms
that higher p53 protein levels are not dependent
on the absence of high-risk viral infection as
shown by the similar immunoreactivity scores of
the HPV-positive and HPV-negative groups.
99,104,105 Tsuda et al. reported that the frequency of
p53 overexpression was 28.6% of 42 CINs and
28.3% of 53 invasive carcinomas.
12
On the other hand, some studies indicate that
immunohistochemical p53 overexpression is not
associated with survival in cervical carcinoma.
12,106
Other studies also show that there is no significant
relationship between p53 expression and pro-
gnosis in squamous cell carcinomas of the uterine
cervix. This is explained partly by the presence of
HPV. The oncogenic potential of HPV appears to
be mediated by the E6 and E7 proteins, which are
known to bind and inactivate the p53 and pRb
proteins, respectively. Furthermore, the HPV E7
oncoprotein has been shown to abrogate p21 and
p27 function.
103,106,107 In addition to inactivation of
the p53 and pRb proteins, other cell cycle regula-
tory proteins may be involved in the carcino-
genesis of cervical cancer.
Other factors
Cyclin A
Cyclin A appears in the nucleus precisely at the
G1/S transition, accumulates throughout the rest
of interphase, and disappears at the beginning of
mitosis. Both cyclin E and cyclin A control the
progression through the cell cycle primarily by
activating CDK2. Cyclin A is important for the
G1-S transition, for progression through the S
phase and for the G2-M transition. Cyclin A binds
to CDK2 in S phase and to CDK1 (cdc2) during
the G2-M transition. This complex induces phos-
phorylation of pRb and the nuclear membrane
protein laminin, augmenting nuclear membrane
disruption. Therefore, cyclin A is essential in the
G1-S and G2-M phase transitions.
108 Forced ex-
pression of cyclin A provides anchorage indepen-
dence to normal cells, and overexpression of
cyclin A is a prognostic factor in different tumor
types. The transcription of cyclin A is induced by
E2F when it is untethered from pRb by the action
of HPV E7 oncoprotein.
75 Cyclin A is overex-
pressed in cervical intraepithelial neoplasia and
SCC compared to normal epithelium.
76,79 Van de
Putte et al. found overexpression of cyclin A in
SCC, consistent with previously described re-
sults.
57 Zehbe et al. demonstrated an overriding of
cyclin-dependent kinase inhibitors by high- and
low-risk HPV: cyclin A and p21
WAF1/CIP1 were co-
expressed in the same cells, mainly in cases of low
grade cervical intra-epithelial neoplasia (LCIN).
109
This provides strong evidence that the p21
WAF1/CIP1
G1 block can be overcome in HPV-infected cells
in vivo. This conclusion is further strengthened by
the result that cyclin A was never found during
the G1 phase of cervical carcinoma-derived cell
lines.
Cyclin B
During the normal cell cycle, cyclin B forms
complexes solely with CDK1 (cdc2 or p34cdc2),
forming the mitosis-promoting factor, which regu-
lates the transition from G2 to M phase.
3,110 The
mitosis-promoting factor is later translocated from
the cytoplasm into the nucleus in late S phase.
Recent evidence has shown that p53 regulates a
G2 checkpoint through cyclin B: p53 prevents the
G2/M transition by decreasing cyclin B protein
levels and attenuating the activity of its pro-
moter.
107
Cho et al. found that cyclin B/p34cdc2 is sig-
nificantly increased in HPV-16 or -18 positive
cervical lesions, including CIN and SCC, in com-
parison with HPV-16 or -18 negative lesions.
107
Southern et al. demonstrated that expression of the
cyclin B protein was up-regulated and persisted
into the upper epithelial layers, in parallel with
cyclin A expression, in HSIL infected with human
papillomaviruses 16, 31, 33, 51, 58, 66, and 67.
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Kanai et al. also found elevated cyclin B levels in
SIL and invasive carcinomas and concomitantly
elevated levels of cdc2, indicating that cyclin B
plays an important role in cervical carcinoge-
nesis.
79 Contrary to the above results, Hashiguchi,
et al. examined HPV status and cyclin B1 in CIN
and invasive cancer by immunohistochemistry.
This study showed that expression of cyclin B1
was 0% in CIN and 12.2% in invasive cancers, and
the relationship between HPV type and cyclin B1
expression was not significant.
111 Further
experimental data are needed to confirm the role
of cyclin B in malignant transformation of the
cervix.
CONCLUSION
Cervical cancer, which plagues women all over
the world, is still a major focus of oncological
research. Infection with HPV has been implicated
as an important etiological factor in the develop-
ment of uterine cervical cancer. Moreover, even in
cases where HPV infection persists, cervical can-
cer most often does not appear until many years
or more than a decade after infection. This long
delay has supported the view that HPV infection
may initiate, but not necessarily cause, progres-
sion to cervical carcinoma, and that oncogenic
influences by other factors such as environmental
factors, specific aspects of lifestyle, or genetic
alterations are necessary to fully establish an
HPV-induced malignancy. Because cancer is a
multi-etiological disease, the time lag between
HPV infection and the diagnosis of cancer also
indicates that multiple steps as well as multiple
factors may be necessary for the development of
cervical cancer.
High-risk HPV types, specifically types 16 and
18, have been demonstrated to participate in
cervical carcinogenesis through the expression of
proteins, such as E6 and E7, interaction with
different steroid hormones, and interaction with
innate genetic susceptibilities to develop cervical
cancer. The results from many studies showed
aberrant alterations in the regulation of several
cell cycle proteins, including cyclin D and E and
p16, p21, and p27, to be characteristic features of
HPV-infected and HPV E6/E7 oncogene-expres-
sing cervical carcinomas and their precursors.
These data suggest further that interactions of
viral proteins with host cellular proteins, parti-
cularly cell cycle proteins, are involved in activa-
tion or repression of cell cycle progression in
cervical carcinogenesis.
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